ロード中...
Phase 1 Trial of the Plasmodium falciparum Blood Stage Vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in Malaria Naïve Adults
BACKGROUND: Merozoite surface protein 1(42) (MSP1(42)) is a leading blood stage malaria vaccine candidate. In order to induce immune responses that cover the major antigenic polymorphisms, FVO and 3D7 recombinant proteins of MSP1(42) were mixed (MSP1(42)-C1). To improve the level of antibody respons...
保存先:
| 主要な著者: | , , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2010
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2809736/ https://ncbi.nlm.nih.gov/pubmed/20107498 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0008787 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|